Abstract
Heart-rate reduction is an important element of patient management during cardiac bypass surgery and in therapeutic measures for combating ischemia and relieving pain in patients with angina. UL-FS 49 is a novel bradycardic agent that purportedly acts solely on the sinoatrial node without potentially deleterious effects on arterial pressure and cardiac inotropism. However, little is known about influences of this agent on neuronal tissue and cardiovascular reflexes. Moreover, left ventricular hypertrophy, which often accompanies cardiovascular disease, is known to attenuate the arterial baroreflex and could have effects interactive with those of UL-FS 49. In this study, the effects of UL-FS 49 on the arterial baroreflex were tested in normal rats (N), rats with left ventricular hypertrophy 14 days after abdominal aortic constriction (AC), and sham-operated controls (SH). Arterial baroreflex sensitivity (BRS) was estimated as the slope of the relation between mean arterial pressure (independent variable) and the RR interval (dependent variable). At the time of study, the AC group had significantly greater mean arterial pressure than either SH or N (159 +/- 2, 122 +/- 3, and 124 +/- 3 mm Hg, respectively; mean +/- SEM, p < 0.01) ...Continue Reading
References
Dec 1, 1992·Journal of Hypertension·H KumagaiT Saruta
Dec 8, 1992·European Journal of Pharmacology·P P Van Bogaert, M Goethals
Feb 1, 1992·Cardiovascular Drugs and Therapy·L J van WoerkensP D Verdouw
Apr 1, 1990·Naunyn-Schmiedeberg's Archives of Pharmacology·T Doerr, W Trautwein
Oct 1, 1991·Journal of Cardiovascular Pharmacology·W E JohnstonW C Little
Dec 1, 1989·Journal of Molecular and Cellular Cardiology·M ChibaH Toshima
Jan 1, 1985·Journal of Cardiovascular Pharmacology·J W DämmgenG J Gross
Jan 1, 1989·Circulation·K A EllenbogenM D Thames
Oct 1, 1988·The American Journal of Physiology·V Fatigati, M J Peach
May 1, 1988·British Journal of Pharmacology·G KrumplG Raberger
Jul 1, 1986·Canadian Journal of Physiology and Pharmacology·F M Siri, R M Smith
Apr 1, 1972·The Journal of Clinical Investigation·C B HigginsE Braunwald
Feb 1, 1970·The American Journal of Physiology·E M Krieger
Apr 1, 1966·Circulation·B M HightowerJ W Kirklin
Jan 1, 1984·European Journal of Clinical Pharmacology·J F GiudicelliA Jacolot
Mar 1, 1994·Neuroscience·H C Pape
Sep 1, 1994·Journal of Cardiovascular Pharmacology·I BriggsC G Heapy
Jan 1, 1995·Clinical and Experimental Pharmacology & Physiology·S SawakiS Chiba
Jul 1, 1995·Journal of Cardiovascular Pharmacology·O PérezJ Tamargo
May 1, 1995·Basic Research in Cardiology·B D Guth, T Dietze
Sep 1, 1993·British Journal of Pharmacology·R E BoSmithN C Sturgess
Nov 1, 1994·British Journal of Pharmacology·W Rouse, I R Johnson
May 1, 1994·Pharmacology·A BrilB Gout
May 1, 1994·British Journal of Pharmacology·C ThollonJ P Vilaine
Jan 1, 1994·Journal of the American College of Cardiology·J C WynsenD C Warltier
May 1, 1993·Journal of Hypertension·N Minami, G A Head
Feb 1, 1993·Journal of the American College of Cardiology·J A BreallW Grossman
Mar 1, 1996·Basic Research in Cardiology·K H RyuJ Ross
Sep 27, 1962·The New England Journal of Medicine·C A CHIDSEYE BRAUNWALD
Sep 1, 1965·The American Journal of Medicine·C A CHIDSEYA G MORROW